-
- 抗原 See all CCL20 抗体
- CCL20 (Chemokine (C-C Motif) Ligand 20 (CCL20))
-
抗原表位
- AA 24-95
-
适用
- 大鼠
-
宿主
- 兔
-
克隆类型
- 多克隆
-
标记
- This CCL20 antibody is un-conjugated
-
应用范围
- Western Blotting (WB), Immunohistochemistry (IHC), Immunocytochemistry (ICC)
- 特异性
- The antibody is a rabbit polyclonal antibody raised against MIP3a. It has been selected for its ability to recognize MIP3a in immunohistochemical staining and western blotting.
- 纯化方法
- Antigen-specific affinity chromatography
- 免疫原
- MIP3a (Glu24-Lys95)
- 亚型
- IgG
- Top Product
- Discover our top product CCL20 Primary Antibody
-
anti-Chemokine (C-C Motif) Ligand 20 (CCL20) antibody (PE)
CCL20 适用: 人 FACS 宿主: 小鼠 Monoclonal UCHL1 PE
anti-Chemokine (C-C Motif) Ligand 20 (CCL20) antibodyCCL20 适用: 人 IP, IHC (p), FACS, IHC (fro) 宿主: 小鼠 Monoclonal UCHL1 unconjugated
anti-Chemokine (C-C Motif) Ligand 20 (CCL20) (AA 24-97) antibodyCCL20 适用: 小鼠 WB, IHC, IP, ICC 宿主: 兔 Polyclonal unconjugated
anti-Chemokine (C-C Motif) Ligand 20 (CCL20) (AA 27-96) antibodyCCL20 适用: 人 WB, IHC, IP, ICC 宿主: 小鼠 Monoclonal A4 unconjugated
anti-Chemokine (C-C Motif) Ligand 20 (CCL20) antibody (FITC)CCL20 适用: 人 FACS 宿主: 小鼠 Monoclonal UCHL1 FITC
anti-Chemokine (C-C Motif) Ligand 20 (CCL20) antibody (PE-DyLight 594)CCL20 适用: 人 FACS 宿主: 小鼠 Monoclonal UCHL1 PE-DyLight 594
anti-Chemokine (C-C Motif) Ligand 20 (CCL20) (AA 31-97) antibodyCCL20 适用: 人, 小鼠 ELISA, IHC (p), IF (cc), IF (p), IHC (fro) 宿主: 兔 Polyclonal unconjugated
anti-Chemokine (C-C Motif) Ligand 20 (CCL20) (AA 24-95) antibodyCCL20 适用: 大鼠 WB, IHC, IP, ICC 宿主: 小鼠 Monoclonal C1 unconjugated
anti-Chemokine (C-C Motif) Ligand 20 (CCL20) (Internal Region) antibodyCCL20 适用: 人, 小鼠 WB, IHC, ELISA, ICC, IF 宿主: 兔 Polyclonal unconjugated
anti-Chemokine (C-C Motif) Ligand 20 (CCL20) antibodyCCL20 适用: 人 WB, ELISA, IHC (p), Func 宿主: 兔 Polyclonal unconjugated
-
- 应用备注
-
- Western blotting: 1:50-400 Immunocytochemistry in formalin fixed cells: 1:50-500 Immunohistochemistry in formalin fixed frozen section: 1:50-500 Immunohistochemistry in paraffin section: 1:10-100 Enzyme-linked Immunosorbent Assay: 1:100-1:5000 Optimal working dilutions must be determined by end user.
- 说明
-
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 浓度
- Lot specific
- 缓冲液
- PBS, pH 7.4, containing 0.02 % Sodium azide, 50 % glycerol.
- 储存液
- Sodium azide
- 注意事项
- WARNING: Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.
- 注意事项
- Avoid repeated freeze-thaw cycles.
- 储存条件
- 4 °C
- 储存方法
- Store at 2-8 °C for one month. Aliquot and store at -80 °C for 12 months.
- 有效期
- 12 months
-
- 抗原
- CCL20 (Chemokine (C-C Motif) Ligand 20 (CCL20))
- 别名
- Macrophage Inflammatory Protein 3 Alpha (MIP3a) (CCL20 产品)
- 别名
- MIP-3ALPHA antibody, CCL20 antibody, si:dkey-150o13.1 antibody, CKb4 antibody, LARC antibody, MIP-3-alpha antibody, MIP-3a antibody, MIP3A antibody, SCYA20 antibody, ST38 antibody, MIP-3A antibody, MIP-3[a] antibody, Scya20 antibody, exodus-1 antibody, C-C motif chemokine ligand 20 antibody, chemokine (C-C motif) ligand 20b antibody, chemokine (C-C motif) ligand 20 antibody, CCL20 antibody, ccl20b antibody, Ccl20 antibody
- 背景
- Alternative Names: CCL20, CKb4, LARC, MIP3-A, SCYA20, ST38, Small Inducible Cytokine Subfamily A(Cys-Cys)Member 20, Beta-Chemokine Exodus-1, Liver And Activation-Regulated Chemokine
- 途径
- The Global Phosphorylation Landscape of SARS-CoV-2 Infection
-
You are here:
